Engineers have modified lipid nanoparticles (LNPs) -- the revolutionary technology behind the COVID-19 mRNA vaccines -- to not only cross the blood-brain barrier (BBB) but also to target specific types of cells, including neurons. This breakthrough marks a significant step toward potential next-generation treatments for neurological diseases like Alzheimer's and Parkinson's.
